F. Shi

Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report

Yao Wang, W. Han, Chun-meng Wang, 2016, Signal Transduction and Targeted Therapy.

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

M. Brock, Q. Mei, W. Han, 2021, Journal for ImmunoTherapy of Cancer.

Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

W. Han, Yao Wang, Hui Fan, 2014, Journal of immunology research.

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

S. Tu, Weili Zhao, Jianxiang Wang, 2023, Cancer biology & medicine.

Analysis of adverse events following the treatment of autologous cytokine-induced killer cells for adoptive immunotherapy in malignant tumour sufferers

W. Han, Yao Wang, L. Xia, 2015, Expert opinion on biological therapy.

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

Yan Zhang, W. Han, Quan-shun Wang, 2015, Oncoimmunology.

Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.

Zhiqiang Wu, W. Han, Yao Wang, 2020, Cytotherapy.

.special Topic: Fighting Cancer with Armed T Cells an Analytical Biomarker for Treatment of Patients with Recurrent B-all after Remission Induced by Infusion of Anti-cd19 Chimeric Antigen Receptor T (car-t) Cells

W. Han, Yao Wang, Chun-meng Wang, 2022 .